MoonLake Immunotherapeutics Sees Unusually High Options Volume (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 2,707 call options on the company. This represents an increase of 142% compared to the typical volume of 1,118 call options.

MoonLake Immunotherapeutics Stock Performance

NASDAQ MLTX traded down $0.93 during midday trading on Monday, hitting $17.33. The company had a trading volume of 2,124,868 shares, compared to its average volume of 1,460,040. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The company has a quick ratio of 8.60, a current ratio of 8.60 and a debt-to-equity ratio of 0.39. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -4.48 and a beta of 1.06. The firm has a fifty day simple moving average of $19.05 and a two-hundred day simple moving average of $17.88.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.08. Equities analysts forecast that MoonLake Immunotherapeutics will post -3.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of MoonLake Immunotherapeutics in a research report on Monday, July 20th. Needham & Company LLC increased their price target on MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th. Finally, Leerink Partners lifted their price target on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Ten equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics has a consensus rating of “Hold” and an average target price of $24.21.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $20.02, for a total transaction of $1,367,145.78. Following the transaction, the chief executive officer directly owned 2,774,893 shares in the company, valued at $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $20.02, for a total value of $1,001,000.00. Following the completion of the sale, the insider directly owned 2,714,746 shares of the company’s stock, valued at $54,349,214.92. This represents a 1.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 344,800 shares of company stock valued at $6,820,071 over the last quarter. 10.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in MoonLake Immunotherapeutics by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock valued at $2,809,000 after purchasing an additional 559 shares during the last quarter. Squarepoint Ops LLC grew its holdings in shares of MoonLake Immunotherapeutics by 3.7% during the second quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock worth $829,000 after purchasing an additional 629 shares during the last quarter. Axiom Investors LLC DE increased its stake in shares of MoonLake Immunotherapeutics by 3.2% in the fourth quarter. Axiom Investors LLC DE now owns 25,998 shares of the company’s stock valued at $343,000 after buying an additional 818 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after buying an additional 1,069 shares in the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in shares of MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after buying an additional 1,158 shares during the last quarter. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.